Advanced Filters
noise

Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Clinical Trials

A listing of Immune (Idiopathic) Thrombocytopenic Purpura (ITP) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 45 clinical trials
Y Yongzhi Zheng, PhD

Short-course High-dose Prednisone and Dexamethasone in Children With ITP

Comparison of the efficacy and safety of short-course high-dose prednisone and dexamethasone in the treatment of children with newly diagnosed immune thrombocytopenia (ITP)

29 - 14 years of age Both Phase 4

An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias

The goal of this clinical study is to evaluate povetacicept in adults with autoimmune cytopenias of immune thrombocytopenia, autoimmune hemolytic anemia, and cold agglutinin disease to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment period participants will receive povetacicept approximately every 4 …

18 - 100 years of age Both Phase 1/2
Y Yi Liu, MD

Low-dose Baricitinib Plus Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia

This is a prospective, multicenter, randomized, controlled phase 2 trial to compare the efficacy and safety profiles in ITP patients receiving baricitinib plus danazol to those receiving danazol alone.

18 - 70 years of age Both Phase 2
M Matthieu MAHEVAS, PHD

IgIV Plus Prednisone vs High-dose Dexamethasone for ITP

ITP patients with low platelet count and active bleeding symptoms are at risk of life-threatening bleeding and therefore require a treatment with a rapid effect, reliable, and sustained. The combination of intravenous immunoglobulin (IVIg) and prednisone (1 mg/kg per day), is more rapidly and more frequently effective than high dose …

18 - 80 years of age Both Phase 3
Y Yi Liu, MD

Low-dose Baricitinib Plus High-dose Dexamethasone for Patients With Newly Diagnosed Immune Thrombocytopenia

A randomized, open-label, multicenter, phase 2 trial to compare the efficacy and safety of baricitinib plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with primary immune thrombocytopenia (ITP).

18 - 70 years of age Both Phase 2
X Xiao-hui Zhang, MD

The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia

To compare the efficacy and safety of teriflunomide plus danazol versus danazol in patients with steroid-resistant/relapse ITP

18 - 80 years of age Both Phase 2
Y Yi Liu, MD

Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia

A randomized, open-label, multicenter study to compare the efficacy and safety of teriflunomide plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with newly diagnosed primary immune thrombocytopenia (ITP).

18 - 80 years of age Both Phase 2
L Li-Ping Yang, MD

Teriflunomide for Steroid-resistant/Relapse Immune Thrombocytopenia

Single-arm, open-label, single-center study to evaluate the efficacy and safety of teriflunomide for the treatment of adults with steroid-resistant/relapse immune thrombocytopenia (ITP).

18 - 80 years of age Both Phase 2
A Alessandra Borchiellini

Biologic Characterization of Patients With ITP

This is a no-profit, multicenter, biological, non-pharmacologic study aimed to characterize from a biological point of view previously untreated primary ITP patients. To this end, peripheral blood, fecal and bone marrow samples will be collected at baseline and at 30 days and 180 days after treatment initiation - for each …

18 - 100 years of age Both Phase N/A
C Catherine Redinger

Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

This is an investigator initiated, multicenter, open label, randomized phase 3 study for subjects with newly diagnosed ITP from ages 1 to less than 18 years old.

1 - 18 years of age Both Phase 3

Rewrite in simple language using AI